Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most core labeling elements (indication, 3 mg dose, repeat dose timing, contraindications, intranasal-only instructions, and storage temperature range format) align. However, several claims are unsupported or inaccurate relative to labeling (notably the effect timing range, “every 15 minutes” retesting, reasons for avoiding post-gastric surgery, and expiration/manufacturer dating and reuse/disposal phrasing).
Category Scores
Accurate Statements
Baqsimi is a nasal spray glucagon device for severe hypoglycemia in adults and children 4 years and older when impaired consciousness prevents oral carbs.
Supported partially. Label: indicated for treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older; intranasal device. Label does not state the condition about “impaired consciousness prevents oral carbs” or limit indication to age ≥4.
Each Baqsimi device delivers one 3 mg dose.
Label description/dosing: 3 mg administered as one actuation; device contains one 3 mg glucagon dose.
If there is no response after 15 minutes, a second dose should be given from a new device if available.
Label: if no response after 15 minutes, additional 3 mg dose from a new device may be administered while waiting for emergency assistance.
If there is no response after 15 minutes, emergency services should be called (e.g., 911).
Partially supported. Label requires emergency assistance when administering and describes waiting for emergency assistance; it does not explicitly mention calling 911.
The used Baqsimi device cannot be reused.
Partially supported. Label says repeat dose may be administered from a new device; it does not explicitly state “cannot be reused” for a used device.
Baqsimi should not be administered to inhale or if both nostrils are blocked during spray.
Partially supported. Label excerpt provided states “BAQSIMI is for intranasal use only” but does not include the specific instruction about nostril blockage or inhalation.
Baqsimi should not be shaken or primed.
Unsupported based on provided label excerpts. No such instructions provided in the supplied label text.
Baqsimi should be stored at 36–77°F (2–25°C) in its pouch, away from heat and freezing.
Partially supported. Storage instructions are not included in the provided label excerpts.
Baqsimi expires 3 years from manufacture.
Unsupported based on provided label excerpts.
Baqsimi should be thrown away after use.
Partially supported. Label indicates repeat dosing uses a new device if needed; it does not provide explicit disposal language in the provided excerpts.
Unsupported Statements
After Baqsimi administration, glucagon raises blood glucose within 10–20 minutes in most cases.
Label excerpts provided do not state a “10–20 minutes in most cases” claim. While clinical study outcomes mention increases within 20 minutes, no “most cases” or “10–20 minutes” phrasing is provided in the supplied text.
After Baqsimi dosing, blood sugar should be retested every 15 minutes.
Label excerpts specify repeat dosing after 15 minutes if no response, but do not recommend retesting blood sugar every 15 minutes.
Baqsimi should not be used if the person can swallow carbs safely.
Label indicates use for severe hypoglycemia but the provided labeling excerpts do not address withholding BAQSIMI when the patient can swallow carbs safely.
Baqsimi should be avoided in post-gastric surgery patients.
Post-gastric surgery avoidance is not listed in provided contraindications/warnings excerpts.
Avoiding Baqsimi in pheochromocytoma, insulinoma, or post-gastric surgery patients is due to risks such as hypertension or nausea.
Label excerpts support contraindications for pheochromocytoma (blood pressure increase) and insulinoma (risk of hypoglycemia). They do not mention “nausea,” and do not provide post-gastric surgery avoidance rationale in the supplied text.
Baqsimi should be skipped in people with known hypersensitivity to glucagon.
Label contraindicates prior hypersensitivity reaction to glucagon or excipients, which is close but “skipped” is not exact label wording. Treated as unsupported/wording mismatch because label specifies contraindication criteria rather than general skipping language.
Baqsimi should not be shaken or primed.
No such administration technique instructions are present in the provided label excerpts.
Baqsimi expires 3 years from manufacture.
No expiration duration is present in provided label excerpts.
Contradictions
Low
AI Statement
Baqsimi is a nasal spray glucagon device for severe hypoglycemia in adults and children 4 years and older...
Label Reference
Indications and Usage: severe hypoglycemia in adults and pediatric patients aged 1 year and older (not 4 years and older specifically).
Important Omissions
Label-supported reason for contraindication/hypersensitivity: BAQSIMI is contraindicated in prior hypersensitivity reaction to glucagon or any excipients (including reported severe allergic reactions).
Importance:
Moderate
Lack of efficacy warning in patients with decreased hepatic glycogen (e.g., starvation, adrenal insufficiency, chronic hypoglycemia).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are either unsupported (e.g., timing “10–20 minutes,” retesting every 15 minutes) or include inaccurate/unsupported patient-category guidance (e.g., post-gastric surgery avoidance) and incomplete labeling of key warnings (decreased hepatic glycogen). These could affect appropriate use and follow-up.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple statements are not supported by the provided FDA label excerpts (especially effect timing phrasing, retesting frequency, post-gastric surgery avoidance, and specific storage/expiration/handling details). One key population limit is inaccurate (label includes pediatric patients ≥1 year, not ≥4 years).
Suggested Improvement
Limit claims to the supplied label wording: severe hypoglycemia in adults and pediatric patients aged 1 year and older; repeat 3 mg from a new device if no response after 15 minutes while waiting for emergency assistance. Remove unsupported details (10–20 minutes “in most cases,” retesting every 15 minutes, post-gastric surgery avoidance, shaking/priming, expiration duration) unless the corresponding label sections are provided.